首页/数据集/Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells

Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells

ChEBI2015-04-09 更新2026-07-21 收录

耐药性前列腺癌

白细胞表达谱分析

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-64143 数据链接链接失效反馈

官方服务：

资源简介：

Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells

应用场景：

创建时间：

2015-04-09

耐药性前列腺癌

雄激素受体信号

Genomic amplification of the androgen receptor (AR) is an established mechanism of antiandrogen resistance in prostate cancer. Here we show that the magnitude of AR signaling output, independent of AR

NIAID Data Ecosystem70

RB-N phosphorylation promotes BRD4-mediated CREB signaling hyperactivation and BET inhibitor resistance

耐药性前列腺癌

靶向治疗联合方案

The combination of CREB inhibitor and JQ1 could overcome the resistance to BET inhibitors in RB loss prostate cancer. Our study firstly showed that GNB1L-CREB pathway was activated after RB loss and c

NIAID Data Ecosystem40

A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer

耐药性前列腺癌

非编码增强子

Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of this locus presumably targeting the AR gen

NIAID Data Ecosystem40

Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells. Homo sapiens

耐药性前列腺癌

差异基因表达分析

Prostate cancer C4-2B cells were cultured in enzalutamide in a dose-escalation manner. After sixty passages cells were resistant to enzalutamide, with a specific sets of genes been deregulated. We per

NIAID Data Ecosystem50

File S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

肿瘤基因组学

耐药性前列腺癌

The table representing the top somatic mutations validated in the COSMIC database were compared between baseline sensitive (N=5) and resistant CTC-DNA (N=5).

NIAID Data Ecosystem40

Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells

资源简介：

相关数据集